NFE2L2 and pancreatic neoplasm: The group of Michael Karin found an increase in several EGFR ligands including EGF after mutationally activated NRF2 in a mouse model of hepatomegaly [34] as well as in human pancreatic cancer cells with ATG7 deletion [49].